-
Broncus Medical Inc. Reports 32% YOY Growth in 2023, Highlighted by Strength in China
•
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung diseases with operations in Shanghai and Hangzhou, China, and San Jose and Seattle, United States, has released its financial report for 2023. The company reported product sales of USD 12.41 million for the period, marking a robust…
-
Broncus Medical and Hangzhou Norchant Terminate Licensing Agreement with Cancellation Fee
•
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations in Shanghai and Hangzhou, China, and San Jose and Seattle, United States, has announced the termination of a licensing agreement between its subsidiary Broncus Medical and Hangzhou Norchant, which was originally signed in September 2021.…
-
Broncus Medical Inc. to Acquire Fibernova Holding Corporation for USD 2.7 Million
•
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations in Shanghai, Hangzhou (China), and San Jose, Seattle (United States), is set to fully acquire Fibernova Holding Corporation for a total consideration of USD 2.7 million. The acquisition includes a USD 1.7 million equity exchange…
